Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Mol Biol Rep ; 47(2): 877-886, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31721021

RESUMO

Diffuse gliomas are the most common malignant primary brain tumors and remain incurable. A better knowledge of the tumor etiology is required. Specific single nucleotides polymorphisms (SNPs) rs4977756 (CDKN2A/B), rs6010620 (RTEL1), rs498872 (PHLDB1), rs2736100 (TERT), and rs4295627 (CCDC26) have been associated with glioma susceptibility and are potential risk biomarkers. This study aimed to analyze five SNPs associated with glioma susceptibility, in the Portuguese population. SNPs were genotyped using the Sequenom MassARRAY platform in 127 gliomas and 180 controls. Unconditional logistic regression models were used to calculate odds ratio (OR) and 95% confidence intervals. The false-positive report probability was also assessed. The associations between polymorphisms and survival were evaluated using the log-rank test. It was found that the AG and GG genotypes of the rs4977756 (CDKN2A/B) were associated with an increased risk of gliomas (OR 1.85 and OR 2.38) and glioblastomas (OR 2.77 and OR 3.94). The GA genotype of the rs6010620 (RTEL1) was associated with a decreased risk of glioblastomas (OR 0.45). We also observed that the GA genotype of the rs498872 (PHLDB1) was associated with an increased risk of gliomas (OR 2.92) and glioblastomas (OR 2.39). No significant risk associations were found for the rs2736100 (TERT) and rs4295627 (CCDC26). In addition, the genotype AA of the rs498872 (PHLDB1) was associated with poor overall survival of gliomas patients (AA vs. GA, p = 0.037). The rs6010620 (RTEL1), rs4977756 (CDKN2A/B), and rs498872 (PHLDB1) are associated with glioma risk in the Portuguese population and these data may contribute to understanding gliomas etiology.


Assuntos
Inibidor p16 de Quinase Dependente de Ciclina/genética , DNA Helicases/genética , Glioma/genética , Peptídeos e Proteínas de Sinalização Intracelular/genética , Proteínas do Tecido Nervoso/genética , Adulto , Alelos , Inibidor de Quinase Dependente de Ciclina p15/genética , Inibidor de Quinase Dependente de Ciclina p15/metabolismo , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , DNA Helicases/metabolismo , Etnicidade , Feminino , Frequência do Gene/genética , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla , Genótipo , Glioblastoma/genética , Glioma/metabolismo , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Masculino , Pessoa de Meia-Idade , Proteínas do Tecido Nervoso/metabolismo , Razão de Chances , Polimorfismo de Nucleotídeo Único/genética , Portugal , Fatores de Risco
2.
Tumour Biol ; 40(3): 1010428318766273, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29584591

RESUMO

The vascular endothelial growth factor regulates angiogenesis that is increased in glioma. VEGF polymorphisms are thought to modulate vascular endothelial growth factor plasma levels and therefore may be implicated in glioma risk. We aimed to clarify the role of VEGF and von Willebrand factor polymorphisms in glioma susceptibility and prognosis. A case-control study of 126 glioma patients and 180 cancer-free controls was performed. Using Sequenom MassARRAY platform, 11 VEGF and 1 VWF polymorphisms were genotyped. Unconditional multivariate logistic regression models were used to calculate odds ratios and 95% confidence intervals. The associations between polymorphisms and survival were evaluated using a Cox regression model. Bonferroni's adjustment was used to correct for multiple testing. The VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblastoma (odds ratio = 155.66), confirmed after Bonferroni correction. Also, the VEGF polymorphisms rs3024994, rs2010963, and particularly the homozygous carriers of rs1005230 were associated with a worse prognosis for glioma and glioblastoma. Our data support a role of VEGF and VWF polymorphisms as glioma biomarkers, with additional potential relevance for molecular stratification of patients for anti-angiogenic therapies.


Assuntos
Biomarcadores Tumorais/genética , Glioma/genética , Glioma/mortalidade , Fator A de Crescimento do Endotélio Vascular/genética , Fator de von Willebrand/genética , Estudos de Casos e Controles , Predisposição Genética para Doença , Glioma/patologia , Humanos , Modelos Logísticos , Análise Multivariada , Neovascularização Patológica/genética , Neovascularização Patológica/patologia , Polimorfismo de Nucleotídeo Único/genética , Portugal , Prognóstico , Fatores de Risco , Fator A de Crescimento do Endotélio Vascular/sangue
3.
J Neurooncol ; 132(1): 27-34, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28083786

RESUMO

Abnormal expression of the long non-coding RNA HOX transcript antisense intergenic RNA (HOTAIR) is oncogenic in several human cancers, including gliomas. The HOTAIR single nucleotide polymorphisms (SNPs) rs920778 (C > T) and rs12826786 (C > T) present in the intronic enhancer and promoter regions of HOTAIR, respectively, are associated with expression, cancer susceptibility, and patient prognosis in some tumor types. However, the relevance of these HOTAIR SNPs has not been studied in glioma. Here, we report a case-control study comprising 177 Portuguese glioma patients and 199 cancer-free controls. All subjects were genotyped by PCR and restriction fragment length polymorphism (RFLP). No statistically significant differences were found in the genotype or allele distributions of either rs920778 or rs12826786 between glioma patients and controls, suggesting these SNPs are not associated with glioma risk. No significant associations were found between rs920778 variants and HOTAIR expression levels, while rs12826786 CT genotype was associated with increased intratumoral HOTAIR RNA levels when compared to TT genotype (p-value = 0.04). Univariate (Log-rank) and multivariate (Cox proportional) analyses showed both rs920778 CT and rs12826786 CT genotypes were significantly associated with longer overall survival of WHO grade III anaplastic oligodendroglioma patients. Our results suggest that HOTAIR SNPs rs920778 and rs12826786 do not play a significant role in glioma susceptibility, but may be important prognostic factors in anaplastic oligodendroglioma patients. Future studies are warranted to validate and expand these findings, and to further dissect the importance of these SNPs in glioma.


Assuntos
Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/genética , Predisposição Genética para Doença , Glioma/diagnóstico , Glioma/genética , RNA Longo não Codificante/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais , Estudos de Casos e Controles , Feminino , Frequência do Gene , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Prognóstico
4.
An. psicol ; 35(2): 181-187, mayo 2019. graf
Artigo em Inglês | IBECS (Espanha) | ID: ibc-181687

RESUMO

In breast cancer patients, quality of life has been associated with treatment response and overall survival. One hundred women undergoing chemotherapy treatment for breast cancer completed questionnaires including demographic and clinical information, the EORTC-Quality of Life Questionnaire, Hospital Anxiety and Depression Scales, Body Image Scale, Index of Family Relations and the Life Orientation Test. The results showed that higher optimism and better body image were associated with improved quality of life. Distress significantly predicted physical and emotional quality of life, but recurrence only predicted physical quality of life. Family stress was a moderator in the relationship between psychological distress and emotional quality of life, showing the need to screen and intervene on family stress in patients with breast cancer. The results may help in designing interventions for women with breast cancer in order to promote quality of life


En pacientes con cáncer de mama, la calidad de vida se ha asociado con la respuesta al tratamiento y la supervivencia global. Cien mujeres sometidas a tratamiento de quimioterapia para el cáncer de mama completaron cuestionarios incluyendo información demográfica y clínica, Cuestionario de Calidad de Vida EORTC, Escalas de Ansiedad y Depresión Hospitalaria, Escala de Imagen Corporal, Índice de Relaciones Familiares y el Test de Orientación Vital. Los resultados mostraron que un mayor optimismo y una mejor imagen corporal se asociaron con una mejor calidad de vida. La morbilidad psicológica predijo significativamente la calidad de vida física y emocional, pero la recurrencia sólo predijo la calidad de vida física. El estrés familiar fue un moderador en la relación entre la morbilidad psicológica y la calidad de vida emocional, mostrando la necesidad de detectar e intervenir en el estrés familiar en pacientes con cáncer de mama. Los resultados pueden ayudar en el diseño de intervenciones para las mujeres con cáncer de mama con el fin de promover la calidad de vida


Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Neoplasias da Mama/psicologia , Qualidade de Vida/psicologia , Família/psicologia , Estresse Psicológico/psicologia , Autoimagem , Perfil de Impacto da Doença , Apoio Social , Relações Familiares/psicologia , Imagem Corporal/psicologia , Estudos Transversais
5.
Oncoimmunology ; 3: e28609, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25097800

RESUMO

Both genetic and environmental factors are thought to be causal in gliomagenesis. Several genes have been implicated in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded γ marker (GM) allotypes exhibit differential sensitivity to an immunoevasion strategy of cytomegalovirus, a pathogen implicated as a promoter of gliomagenesis, has lead us to hypothesize that these determinants are risk factors for glioma. To test this hypothesis, we genotyped the IGHG locus comprising the GM alleles, specifically GM alleles 3 and 17, of 120 glioma patients and 133 controls via TaqMan® genotyping assay. To assess the associations between GM genotypes and the risk of glioma, we applied an unconditional multivariate logistic regression analysis adjusted for potential confounding variables. In comparison to subjects who were homozygous for the GM 17 allele, the GM 3 homozygotes were over twice as likely, and the GM 3/17 heterozygotes were over three times as likely, to develop glioma. Similar results were achieved when analyzed by combining the data corresponding to alleles GM 3 and GM 3/17 in a dominant model. The GM 3/17 genotype and the combination of GM 3 and GM 3/17 were found to be further associated with over 3 times increased risk for high-grade astrocytoma (grades III-IV). Allele frequency analyses also showed an increased risk for gliomas and high-grade astrocytoma in association with GM 3. Our findings support the premise that the GM 3 allele may present risk for the development of glioma, possibly by modulating immunity to cytomegalovirus.

6.
Cancer Epidemiol Biomarkers Prev ; 20(12): 2610-7, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21960689

RESUMO

BACKGROUND: The epidermal growth factor receptor (EGFR) regulates important cellular processes and is frequently implicated in human tumors. Three EGFR polymorphisms have been described as having a transcriptional regulatory function: two single-nucleotide polymorphisms in the essential promoter region, -216G/T and -191C/A, and a polymorphic (CA)(n) microsatellite sequence in intron 1. We aimed to elucidate the roles of these EGFR polymorphisms in glioma susceptibility and prognosis. METHODS: We conducted a case-control study with 196 patients with glioma and 168 cancer-free controls. Unconditional multivariate logistic regression models were used to calculate ORs and 95% confidence intervals. A Cox regression model was used to evaluate associations with patient survival. False-positive report probabilities were also assessed. RESULTS: None of the EGFR -216G/T variants was significantly associated with glioma risk. The -191C/A genotype was associated with higher risk for glioma when the (CA)(n) alleles were classified as short for ≤16 or ≤17 repeats. Independently of the (CA)(n) repeat cutoff point used, shorter (CA)(n) repeat variants were significantly associated with increased risk for glioma, particularly glioblastoma and oligodendroglioma. In all tested models with different (CA)(n) cutoff points, only -191C/A genotype was consistently associated with improved survival of patients with glioblastoma. CONCLUSIONS: Our findings implicate EGFR -191C/A and the (CA)(n) repeat polymorphisms as risk factors for gliomas, and suggest -191C/A as a prognostic marker in glioblastoma. IMPACT: Our data support a role of these EGFR polymorphisms in determining glioma susceptibility, with potential relevance for molecularly based stratification of patients with glioblastoma for individualized therapies.


Assuntos
Neoplasias Encefálicas/genética , Receptores ErbB/genética , Glioma/genética , Neoplasias Encefálicas/enzimologia , Estudos de Casos e Controles , Feminino , Genótipo , Glioma/enzimologia , Humanos , Masculino , Polimorfismo Genético , Polimorfismo de Nucleotídeo Único , Prognóstico , Regiões Promotoras Genéticas , Fatores de Risco
7.
Oncol Rep ; 23(6): 1655-62, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20428822

RESUMO

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol). The Kaplan-Meier method was used to construct survival curves, and the log-rank test and a Cox-regression model were used to analyze patient survival. The methylation status of MGMT was successfully determined in 89% (80/90) of the tumors. The frequency of tumoral MGMT promoter methylation was 47.5%. The median overall survivals (OSs) were 16 months (95% CI 12.2-19.8) and 13 months (95% CI 13.3-18.7) for patients whose tumors had a methylated or unmethylated MGMT, respectively. Univariate and multivariate analyses did not show any statistically significant association between MGMT methylation status and patient OS (P=0.583 by the log-rank test; P=0.617 by the Cox-regression test) or progression-free survival (P=0.775 by the log-rank test; P=0.691 by the Cox-regression test). None of the patient clinical features were significantly correlated with survival. This is the first study to report the frequency of MGMT methylation among Portuguese GBM patients. Our data did not show statistically significant associations between MGMT promoter methylation and the outcome of GBM patients treated with temozolomide. Additional robust prospective studies are warranted to clarify whether the MGMT status should be used in clinical decisions.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias Encefálicas/genética , Metilação de DNA , Dacarbazina/análogos & derivados , Glioblastoma/genética , O(6)-Metilguanina-DNA Metiltransferase/genética , Regiões Promotoras Genéticas/genética , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/terapia , Terapia Combinada , Dacarbazina/uso terapêutico , Feminino , Glioblastoma/patologia , Glioblastoma/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Portugal , Dosagem Radioterapêutica , Taxa de Sobrevida , Temozolomida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA